Leadership Overview
Curia has 8 executives leading key functions including strategy, human resources, information technology, finance, and operations.
Driven by innovation, Curia is dedicated to advancing pharmaceutical and biopharmaceutical solutions through comprehensive contract research, development, and manufacturing services, impacting global health outcomes.
Driven by innovation, Curia is dedicated to advancing pharmaceutical and biopharmaceutical solutions through comprehensive contract research, development, and manufacturing services, impacting global health outcomes.
Leadership Roles at Curia
Sam Yasine - Chief Executive Officer
Sam Yasine, the Chief Executive Officer at Curia, directs the overarching corporate strategy and operational execution for the contract research, development, and manufacturing organization. Overseeing all business units, Sam Yasine ensures alignment with the company's mission to serve pharmaceutical and biopharmaceutical clients from initial research through commercial production. This leadership role involves driving market expansion and fostering innovation across all service offerings. By optimizing resource allocation and strategic partnerships, Sam Yasine directly impacts the company's ability to deliver integrated solutions. Ultimately, Yasine secures long-term growth and market leadership in the biopharmaceutical services sector. The Chief Executive Officer's purview encompasses global operations, ensuring seamless integration of R&D, manufacturing, and client services to meet evolving industry demands and regulatory standards.
Alex Milenkovic - Founder & Chief Executive Officer
Alex Milenkovic, the Founder & Chief Executive Officer at Curia, established the organization's foundational principles and continues to guide its strategic vision. As Founder & Chief Executive Officer, Alex Milenkovic champions the company's commitment to providing end-to-end solutions for pharmaceutical and biopharmaceutical customers, spanning research, development, and commercial manufacturing. This executive position involves cultivating a culture of scientific excellence and operational efficiency. By leveraging deep industry expertise, Alex Milenkovic ensures the company remains at the forefront of innovation, addressing complex client needs. The Founder & Chief Executive Officer's influence extends to shaping the company's long-term trajectory and market positioning. Milenkovic's leadership is critical in maintaining the company's reputation for quality and reliability in a highly regulated industry.
Gerald Auer - Group Chief Financial Officer
Gerald Auer, the Group Chief Financial Officer at Curia, oversees all financial planning, reporting, and capital management activities. Directing the finance and accounting departments, Gerald Auer ensures the fiscal health and strategic financial direction of the contract research, development, and manufacturing organization. This executive role involves managing budgets, optimizing cash flow, and driving financial performance to support Curia's growth objectives in the pharmaceutical and biopharmaceutical sectors. By implementing rigorous financial controls and strategic investment plans, Gerald Auer directly enhances the company's profitability and shareholder value. Auer's leadership is crucial for maintaining financial transparency and compliance with global accounting standards. The Group Chief Financial Officer's responsibilities include securing funding, managing risk, and providing critical financial insights to support executive decision-making and long-term sustainability.
Kourtney Forster - President
Kourtney Forster, the President at Curia, drives strategic initiatives and operational oversight across key business segments. As President, Kourtney Forster ensures the seamless execution of the company's contract research, development, and manufacturing services, supporting pharmaceutical and biopharmaceutical clients. This leadership role involves fostering cross-functional collaboration and optimizing resource deployment to meet market demands. By championing operational excellence and client-centric approaches, Kourtney Forster directly contributes to Curia's reputation for reliability and innovation. Forster's focus includes enhancing service delivery and expanding market reach. The President's responsibilities are integral to achieving the company's mission of advancing drug development and manufacturing solutions globally.
Ronald Aungst - President, Drug Product
Ronald Aungst, the President, Drug Product at Curia, leads the strategic direction and operational execution for all drug product development and manufacturing activities. Overseeing formulation, fill-finish operations, and commercial supply, Ronald Aungst ensures the delivery of high-quality pharmaceutical products to clients. This executive position involves driving efficiency and innovation within the drug product division, supporting the company's comprehensive service offerings for the pharmaceutical and biopharmaceutical industries. By optimizing manufacturing processes and supply chain logistics, Ronald Aungst directly enhances Curia's capacity to meet client timelines and quality standards. Aungst's leadership is vital for maintaining regulatory compliance and advancing the company's capabilities in drug product manufacturing. The President, Drug Product's role is critical in translating scientific advancements into commercially viable treatments.
James Grabowski - President, Research & Development
James Grabowski, the President, Research & Development at Curia, directs the company's scientific innovation and early-stage development services. Overseeing all contract research operations, James Grabowski ensures the delivery of cutting-edge solutions for pharmaceutical and biopharmaceutical clients, from discovery through preclinical development. This leadership role involves fostering a culture of scientific inquiry and advancing novel research methodologies. By driving R&D excellence and strategic scientific partnerships, James Grabowski directly contributes to Curia's ability to solve complex scientific challenges. Grabowski's expertise is essential for expanding the company's research capabilities and supporting the development of new therapeutics. The President, Research & Development's focus is on accelerating the drug discovery pipeline and providing robust scientific support for clients' programs.
Joseph Sangregorio - Chief Human Resources Officer
Joseph Sangregorio, the Chief Human Resources Officer at Curia, architects the global talent strategy and organizational development initiatives. Overseeing all human capital functions, Joseph Sangregorio ensures the company cultivates a high-performing workforce capable of supporting complex pharmaceutical and biopharmaceutical R&D and manufacturing operations. This executive role involves developing robust recruitment, retention, and employee engagement programs. By fostering a supportive and inclusive work environment, Joseph Sangregorio directly contributes to the company's ability to attract and retain top scientific and operational talent. Sangregorio's leadership is essential for aligning human resources with the company's strategic objectives, driving operational excellence and innovation across all departments. The Chief Human Resources Officer's responsibilities include managing compensation, benefits, and compliance to support Curia's global presence.
Gregory Kuzma - Senior Vice President, Chief Information Officer
Gregory Kuzma, the Senior Vice President, Chief Information Officer at Curia, directs the enterprise-wide information technology strategy and infrastructure. Overseeing all digital operations and cybersecurity measures, Gregory Kuzma ensures robust, scalable, and secure IT systems that support the company's contract research, development, and manufacturing services for pharmaceutical and biopharmaceutical clients. This leadership position involves implementing advanced technological solutions to enhance operational efficiency and data integrity. By driving digital transformation initiatives, Gregory Kuzma directly enables seamless collaboration and data management across R&D and manufacturing functions. Kuzma's expertise is critical in safeguarding sensitive client data and intellectual property, maintaining compliance with industry regulations. The Senior Vice President, Chief Information Officer's focus includes optimizing IT resources to support Curia's global business objectives and innovation pipeline.
Explore Leadership Teams in Manufacturing
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. Together, were rapidly becoming one of the most dynamic, purpose-driven pharmaceutical companies delivering more affordable access to essential medicines. Today, Amneal is much more than generics. A series of strategic investments over the years has bolstered our world-class scientific rigor, production capabilities and commercial infrastructure. We have also invested substantially in our people through leadership development and employee well-being programs. Together, these advancements have accelerated our ability to deliver innovation, more complex products and broadened portfolios in new categories and geographies. Two decades after our founding, Amneal is better positioned than ever to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrows health challenges. We are Amneal and We make healthy possible.
Company Leadership
HK
ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Companys range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
Company Leadership FJ
Jamjoom Pharma is one of the leading pharmaceutical companies in the Afrasia region focused on the Middle East, Africa, and CIS countries. Based in Jeddah, Saudi Arabia, Jamjoom Pharma manufactures and markets pharmaceutical products, over the counter (OTC) medicines, and health related consumer products. The company is owned by the Jamjoom Group.
Company Leadership NS
TH
AM
AH
Founded in 1850 and headquartered in Johannesburg, South Africa, Aspen Pharmacare Holdings Limited is a global specialty and branded pharmaceutical company headquartered in Durban, South Africa. Operating across Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia, Aspen focuses on sterile injectables (including anaesthetics, anticoagulants, antithrombotics, analgesics, and hormone replacement therapies), over-the-counter medicines, and prescription products for conditions such as hypothyroidism, autoimmune disease, pain, gout, and inflammatory disorders. The company also manufactures active pharmaceutical ingredients and finished dose forms, including steriles, oral solids, liquids, semi-solids, biologicals, and heparins, supplying both its own brands and third-party customers worldwide.
Company Leadership
TS
RM
Frequently Asked Questions Regarding Curia Top Executives and Leadership Team
